Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
The following is a summary of the Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript:
以下是第一三共有限公司（DSKYF）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Daiichi Sankyo's FY 2023 revenue increased 25.3% year-on-year to ¥1.6017 trillion, led by its oncology business.
Core operating income grew 59.3% year-on-year to ¥195.3 billion, operating income increased by 75.5% to ¥211.6 billion, and net income rose by 83.8% to ¥207 billion.
They expect a revenue of ¥2.1 trillion for FY 2025 which is an increase by ¥100 billion from the previous year due to oncology sales.
The core operating profit ratio is targeted to be 40% before R&D expense, and a DOE of 8.5% or more is expected, surpassing their previous goal of 8%.
The company reported FY 2023 income of ¥235 billion before tax.
在腫瘤業務的帶動下，第一三共2023財年的收入同比增長25.3％，達到1.6017萬億日元。
核心營業收入同比增長59.3％，達到1,953億日元，營業收入增長75.5％，達到2116億日元，淨收入增長83.8％，達到2070億日元。
他們預計，2025財年的收入爲2.1萬億日元，由於腫瘤學的銷售，比上年增加了1000億日元。
扣除研發費用前的核心營業利潤率目標爲40％，預計DOE爲8.5％或以上，超過其先前設定的8％的目標。
該公司報告稱，2023財年的稅前收入爲2350億日元。
Business Progress:
業務進展：
Daiichi Sankyo secured approval for and initiated the promotion of ENHERTU, contributing majorly to its oncology business growth.
The company has submitted applications for regulatory approval in the US and Europe for non-squamous, non-small cell lung cancer.
The company's strategic alliance with Merck is expected to boost oncology sales revenue.
The company aims to be among the top ten companies in oncology by 2030 and plans to invest ¥1 trillion in R&D for FY 2024 and 2025 to achieve this.
The company has discontinued the development of DS-1594, the Menin binding inhibitor, due to lower enrollment and interest among patients and investigators.
Daiichi Sankyo achieved an increment in sales revenue that exceeded the initial expectations, particularly due to the company's major products that recorded solid growth.
第一三共獲得批准並啓動了ENHERTU的推廣，爲其腫瘤業務增長做出了重大貢獻。
該公司已向美國和歐洲提交了非鱗狀非小細胞肺癌的監管批准申請。
公司與默沙東的戰略聯盟預計將增加腫瘤學的銷售收入。
該公司的目標是到2030年成爲腫瘤學領域的十大公司之一，並計劃在2024和2025財年投資1萬億日元用於研發，以實現這一目標。
由於患者和研究者的入組人數減少以及他們的興趣，該公司已停止開發Menin結合抑制劑 DS-1594。
第一三共實現了銷售收入的增長，超出了最初的預期，這主要是由於該公司的主要產品實現了穩步增長。
More details: DAIICHI SANKYO COMPANY LIMITED IR
更多詳情： 第一三共株式會社
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。